Quince Therapeutics (QNCX) vs Scilex (SCLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Scilex (SCLX) has outperformed Quince Therapeutics (QNCX) over the past year, losing 73.0% versus a loss of 92.2%. Over five years, SCLX leads with a -98.6% price change compared with -99.8% for QNCX. Quince Therapeutics is the larger company by market cap ($32.3 million vs $20.5 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QNCX | SCLX |
|---|---|---|
| Share price | $31.73 | $2.92 |
| Market cap | $32.27M | $20.54M |
| 1-day change | +8.07% | -1.35% |
| YTD return | -95.26% | -61.03% |
| 1-year return | -92.22% | -72.96% |
| 5-year return | -99.77% | -98.65% |
| Forward P/E | — | 4.00 |
| EPS (TTM) | $-214.01 | $-48.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $910.00 | $16.81 |
| 52-week low | $15.10 | $2.62 |
| Distance from 52-week high | -96.51% | -82.63% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +137.72% | — |
| Average volume | 28.83K | 54.13K |
| Shares outstanding | 1.02M | 7.03M |
| Employees | 38 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SCLX has outperformed QNCX by 19.3 percentage points over the past year.
About Quince Therapeutics
QNCX stock →Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 38 employees
About Scilex
SCLX stock →Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees
QNCX vs SCLX FAQ
Which is bigger, Quince Therapeutics or Scilex?
Quince Therapeutics (QNCX) is larger, with a market capitalization of $32.27M compared with $20.54M for Scilex (SCLX).
Which stock has performed better over the past year, QNCX or SCLX?
SCLX returned -72.96% over the past 12 months, compared with -92.22% for QNCX (price return, excluding dividends). Past performance does not predict future results.
Are Quince Therapeutics and Scilex in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.